» Authors » Jean-Philippe Metges

Jean-Philippe Metges

Explore the profile of Jean-Philippe Metges including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 55
Citations 1998
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Lecomte T, Giraudeau B, Phelip J, Tournigand C, Ducreux M, Tougeron D, et al.
Dig Liver Dis . 2025 Mar; PMID: 40044552
Bevacizumab shows inter-individual pharmacokinetic variability, with an exposure-response relationship in metastatic colorectal cancer (mCRC) patients. This study explores whether a double dose of bevacizumab, compared to a standard dose, increases...
2.
Thereaux J, Badic B, Fuchs B, Leven C, Caillard A, Lacut K, et al.
Surgery . 2025 Feb; 181:109171. PMID: 39952022
Background: Venous thromboembolism is a well-recognized complication after hepatopancreatobiliary surgery. However, there is a paucity of nationwide data on risk factors and incidence within 1 year of surgery in patients...
3.
Nguyen V, Metges J, Morjani M, Pourreau P, Dhamelincourt E, Queneherve L, et al.
Radiat Oncol . 2024 Dec; 19(1):175. PMID: 39696537
Introduction: While there is a growing amount of data on the cardiac toxicity of radiotherapy (RT) in relation to its impact on cardiac sub-structures (CSS), there are only few studies...
4.
Tougeron D, Bibeau F, Chibaudel B, Kim S, Nguyen T, Phelip J, et al.
Eur J Cancer . 2024 Nov; 213():115082. PMID: 39486163
Aim: To evaluate R0/R1 resection rate in patients with colorectal liver metastases (CLM) treated with aflibercept plus FOLFIRI after failure of a prior oxaliplatin-based regimen in daily clinical practice. Methods:...
5.
Thuillier P, Bourhis D, Pavoine M, Metges J, Le Pennec R, Schick U, et al.
Front Nucl Med . 2024 Oct; 2:941848. PMID: 39390995
Rational: To validate a population-based input function (PBIF) model that alleviates the need for scanning since injection time in dynamic whole-body (WBdyn) PET. Methods: Thirty-seven patients with suspected/known well-differentiated neuroendocrine...
6.
Philip P, Sahai V, Bahary N, Mahipal A, Kasi A, Rocha Lima C, et al.
J Clin Oncol . 2024 Aug; 42(31):3692-3701. PMID: 39088774
Purpose: Metastatic pancreatic adenocarcinoma (mPC) remains a difficult-to-treat disease. Fluorouarcil, oxaliplatin, irinotecan, and leucovorin (FFX) is a standard first-line therapy for mPC for patients with a favorable performance status and...
7.
Mansoor W, Joo S, Norquist J, Kato K, Sun J, Shah M, et al.
Oncologist . 2024 May; 29(10):e1324-e1335. PMID: 38815152
Background: In the KEYNOTE-590 study, first-line pembrolizumab plus chemotherapy provided statistically significant improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy, with a manageable safety profile...
8.
Thereaux J, Badic B, Fuchs B, Caillard A, Geier M, Lacut K, et al.
Ann Surg Oncol . 2024 Mar; 31(6):3984-3994. PMID: 38485867
Background: French policymakers recently chose to regulate high-risk digestive cancer surgery (DCS). A minimum of five cases per year should be performed for each of the following types of curative...
9.
10.
Neuzillet C, Bouche O, Tournigand C, Chibaudel B, Bauguion L, Bengrine-Lefevre L, et al.
J Natl Compr Canc Netw . 2023 Dec; 21(12):1234-1242.e17. PMID: 38081120
Background: The impact of adapted physical activity (APA) on health-related quality of life (HRQoL) in patients with advanced pancreatic ductal adenocarcinoma (aPDAC) is unknown. This study evaluated whether APA in...